PRWeb The Leader Press Release Distribution
See How PRWeb Works

We're here to help 1-866-640-6397

Login Create Free Account


All Press Releases for October 22, 2009 Add to my Yahoo! Subscribe to this News Feed Subscribe to this News Feed   
 

Sinus Dynamics Announced Treatment for MRSA with Nasal Nebulizer and Vancomycin

Vancomycin is used to treat bacterial infections by stopping or killing the bacteria responsible. When treatment using other antibiotics has failed, Vancomycin is the strongest option available. Now through Sinus Dynamic , Vancomycin is available in an aerosolized topical form which is effective against MRSA.

Westlake Village, CA (PRWEB) October 22, 2009 -- Sinus Dynamics™ announced today that the company has discovered treatment for Methicillin Resistant Staphylococcus Aureus (MRSA) with a nasally inhaled aerosolized form of Vancomycin, which can help patients and hospitals limit exposure to asymptomatic MRSA carriers.

sinus Infection
sinus Infection

Sinusitis Treatment with 82% succses rate rather than Sinus Surgery
Pharmacists at Sinus Dynamic can help the medical professionals address one of the largest fears of physicians, hospital administrators and patients alike (Hospital Acquired Infections). The Centers for Disease Control and Prevention estimates that hospital acquired infections are a direct result of 90,000 patient deaths each year in the U.S.A., while other organizations claim that the number is much higher.

Sinus Dynamics is the nation's leading compounding pharmacy specializing exclusively in the research and development of aerosolized formulas to treat bacterial and fungal sinus infections, sinus inflammation, and acute and chronic sinusitis. Sinus Dynamics treatments are self-administered by the patient using a small lightweight, electronic nebulizer. This medical device creates a 3.2 micron medicated mist, consisting of antibiotic, anti-fungal or anti-inflammatory medications. The medicated mist penetrates the sinus cavities to topically treat sinuses infected with MRSA or any other bacterial or fungal infection. With industry leading technology that enables physicians from across the country to prescribe our topical treatment method for their refractory sinus patients; Sinus Dynamics has the experience and resources in place to confront MRSA at its source; in the asymptomatic, sinus colonized MRSA carrier.

Sinus Dynamics is prepared to work with physicians and hospital administrators to implement this infection control therapy in an effort to help reduce MRSA infections across the country.

Contact Sinus Dynamics™ , a division of General Home Pharmacy, Inc. at 877-447-4276 or through their web site at www.sinusdynamics.com . Sinus Dynamics works with otolaryngologists, allergy & immunology specialists, infectious disease specialists, and pulmonary specialists throughout the United States; providing custom compounded medications, exclusively formulated to treat upper respiratory infections and inflammation through topical treatment. A network of representatives is available for on-site demonstrations.

###

Post Comment:
Trackback URL: http://www.prweb.com/pingpr.php/WmV0YS1TcXVhLUhhbGYtUHJvZi1GYWx1LUNvdXAtWmVybw==

Bookmark -  Del.icio.us | Furl It | Technorati | Ask | MyWeb | Propeller | Live Bookmarks | Newsvine | TailRank | Reddit | Slashdot | Digg | Stumbleupon | Google Bookmarks | Sphere | Blink It | Spurl


OPTIONS
Printer Friendly Printer Friendly Version
Adobe PDF Download PDF Version
Adobe PDF Download Reader Version
Blog This BlogThis
Share This ShareThis
CONTACT INFORMATION
Kambiz Yadidi
General Home Pharmacy
877-447-4276 x221
Email us Here
ATTACHED FILES

There are no multimedia files attached to this release. If this is your release, you may add images or other multimedia files through your PRWeb News Management Console.

ABOUT PRESS RELEASES
If you have any questions regarding information in these press releases please contact the company listed in the press release. Please do not contact PRWeb. We will be unable to assist you with your inquiry. PRWeb disclaims any content contained in these release. Our complete disclaimer appears here.
 
Close Move